LexisNexis® Legal Newsroom
Johnson & Johnson Reserves $600M To Settle Risperdal, Invega, Natrecor Civil Cases

NEW BRUNSWICK, N.J. - (Mealey's) Johnson & Johnson (J&J) expects to incur a special charge against earnings of about $600 million in the second quarter for the potential settlement of civil litigation related to Risperdal, Invega, Natrecor and Omnicare Inc., according to a Form 8-K report...